Talking Urology

International Experts

ANZUP 2017 Talking Urology Series #1_ Peter Black - Changes in immunotherapy in bladder cancer

 

Peter Black discusses lessons learned from immunotherapy in bladder cancer and what we might need to look out for in prostate cancer.

ANZUP 2017 Talking Urology Series #2_ Ada Cheung - Hypogonadism in testicular cancer patients

 

Ada Cheung discusses the often-missed diagnosis of hypogonadism in men who have had treatment for testicular cancer.

ANZUP 2017 Talking Urology Series #3_ Silke Gillessen - Advanced prostate cancer consensus conference

 

Silke Gillessen discusses the interesting findings from the Advanced Prostate Cancer Consensus Conference in St Gallen

ANZUP 2017 Talking Urology Series #4_ Lisa Horvath - Plasma lipid signature in castrate resistant prostate cancer

 

Lisa Horvath discusses her research on how a man's plasma lipid signature can predict prognosis in castration resistant prostate cancer

ANZUP 2017 Talking Urology Series #5_ Alexander Kutikov - Response to therapy prior to cystectomy

 

Alex Kutikov discusses if can we predict pT0 after neoadjuvant chemotherapy and do we need to continue to cystectomy?

ANZUP 2017 Talking Urology Series #6_ David Quinn - Pembrolizumab in bladder cancer

 

David Quinn presents results from the KEYNOTE-045 study investigating second line pembrolizumab in patients with advanced bladder cancer

ANZUP 2017 Talking Urology Series #7_ Matthew Roberts - Improving biomarkers for prostate cancer

 

Matthew Roberts discusses his research on how seminal plasma (ejaculate) can be used to monitor men on active surveillance for prostate cancer

ANZUP 2017 Talking Urology Series #8_ Dennis Taaffe - Exercise physiology trial with patients from RADAR study

 

Dennis Taaffe discusses the RADAR study investigating the benefits of exercise in men undergoing treatment for prostate cancer

Dr. Daniel W. Lin speaks with Joseph

 

Dr. Daniel W. Lin is the Chief of Urologic Oncology at the University of Washington’s Department of Urology and a urologist specializing in genitourinary oncologic surgery, early detection and prevention, and basic research.

Dr. Lin’s major basic/translational research interests are in prostate chemoprevention and molecular/genomic biomarkers for aggressive prostate cancer, and his major clinical research efforts are in prostate cancer active surveillance and novel strategies in high-risk prostate cancer.

Dr Joseph Ischia talks to Dr Stacy Loeb about the management of prostate cancer in New York and the role of social media in medicine

 

Dr Loeb is an Assistant Professor of Urology and Population Health at New York University, specializing in prostate cancer.

Dr. Loeb attended medical school at Northwestern University and completed her urology residency training at Johns Hopkins. She is also a recognized expert on social media in medicine.

Dr David Quinn discusses the Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

 

Dr. Quinn is currently the Medical Director of the Norris Cancer Hospital, the Head of Genitourinary Medical Oncology and Associate Professor of Medicine in the Division of Oncology, Keck School of Medicine, University of Southern California. He is a medical oncologist and an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics.

A/Prof Shahrokh Shariat discusses the Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series from the Bladder Cancer Research Consortium

 

A/Prof Shariat is currently professor and chairman of the department of urology, Medical University of Vienna General Hospital, Austria. He is also adjunct professor of urology and medical oncology at Weill Cornell Medical Center, New York, and adjunct professor or urology at the University of Texas Southwestern Medical Center, Dallas, USA.